Clinical Core

临床核心

• 批准号: 10620816
• 负责人: CHRISTOPHER H VAN DYCK
• 金额: $ 77.03万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10620816
• 关键词: Acceleration; Action Research; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Alzheimer’s disease biomarker; Autopsy; Biological; Biological Markers; Categories; Cessation of life; Classification; Clinical; Clinical Research; Cognitive; Collaborations; Collection; Consent; Data Set; Dementia; Development; Diagnostic; Diagnostics Research; Disease; Early Diagnosis; Enrollment; Evaluation; Exclusion Criteria; First Degree Relative; Future; Goals; Image; Liquid substance; Longitudinal Studies; Measures; Methods; NIH Program Announcements; Nerve Degeneration; Neurosciences; Participant; Pathogenesis; Pathologic; Patients; Plasma; Population; Protocols documentation; Research; Research Personnel; Research Project Grants; Research Support; Resources; Serum; Specimen; Synapses; System; Target Populations; Testing; Therapeutic; Time; Training; Whole Blood; Work; abeta deposition; biomarker validation; data management; disease phenotype; education research; follow up assessment; imaging study; improved; inclusion criteria; interest; middle age; mild cognitive impairment; neuroimaging; neuropathology; nonalzheimer dementia; outreach; participant enrollment; pre-clinical; prevent; programs; recruit; repository; research study; study population; tau Proteins; therapeutic development; therapy development; translational scientist; validation studies

SUMMARY OF THE CLINICAL CORE The over-arching goal of the Core will be to provide research diagnostic evaluations for a large clinical population with a special emphasis on participants who are followed longitudinally and tracked to autopsy to provide well-characterized participants for the research projects conducted by ADRC investigators and collaborators. Important focuses of the Clinical Core—as for the Yale ADRC broadly—include cellular neuroscience, synaptic mechanisms, and an emphasis on systematic storage of biospecimens for current and future biomarker studies. The importance of neuroimaging and fluid biomarkers for AD diagnosis and therapeutic development is increasing well appreciated, and recent research has emphasized the importance of classifying patients according to the presence of β-amyloid deposition, pathologic tau, and neurodegeneration (ATN). The Yale ADRC Imaging, Biomarker, and Neuropathology Cores and specific Developmental Projects will seek to develop these methods with relevance to AD and related disorders. In partnership with these efforts, the Clinical Core will undertake the collection of a wide range of imaging studies and fluid biomarker specimens across the full spectrum of AD cross-sectionally and during the full course of AD longitudinally. Aim 1 will maintain the Core Population through enrollment of 250 new participants on the full continuum of AD (from preclinical to dementia), as well as non-AD dementias and normal controls. Aim 2 will enroll these participants in the Uniform Data Set (UDS) population and make the UDS measures available to the National Alzheimer’s Coordinating Center (NACC) for national studies. Aim 3 will enroll subjects into the Autopsy Program. Aim 4 will provide appropriate subjects for the clinical studies affiliated with the ADRC. Aim 5 will collect biological specimens for Yale ADRC and other researchers for biomarker studies. Aim 6 will assist the Research Education Core in training future clinical and translational researchers in AD and related disorders. These Aims will provide ADRC affiliated investigators the ready ability to test biomarkers—once validated in AD dementia—in the earliest stages of AD pathogenesis.

临床核心总结 核心的首要目标是为大型临床提供研究诊断评估 人群，特别强调纵向跟踪并跟踪尸检的参与者 为 ADRC 研究人员进行的研究项目提供具有良好特征的参与者 合作者。临床核心的重要焦点——对于耶鲁大学 ADRC 来说更广泛——包括细胞 神经科学、突触机制，以及强调当前和未来生物样本的系统存储 未来的生物标志物研究。神经影像学和液体生物标志物对于 AD 诊断和治疗的重要性 治疗的发展越来越受到人们的重视，最近的研究强调了治疗的重要性 根据是否存在 β-淀粉样蛋白沉积、病理性 tau 蛋白和 神经变性（ATN）。耶鲁大学 ADRC 成像、生物标志物和神经病理学核心和特定 发展项目将寻求开发与 AD 和相关疾病相关的这些方法。在 通过与这些工作的合作，临床核心将收集广泛的影像学研究 以及 AD 整个谱系的液体生物标志物样本以及整个过程中的横截面 AD纵向。目标 1 将通过注册 250 名新参与者来维持核心人口 AD 的完整连续体（从临床前到痴呆），以及非 AD 痴呆和正常对照。目标2 将把这些参与者纳入统一数据集 (UDS) 群体，并提供 UDS 测量值 国家阿尔茨海默病协调中心 (NACC) 进行国家研究。目标 3 将受试者纳入 尸检计划。目标 4 将为 ADRC 附属的临床研究提供适当的受试者。目的 5号将为耶鲁大学ADRC和其他研究人员收集生物样本，用于生物标志物研究。目标 6 将有所帮助 研究教育核心，培训未来 AD 及相关领域的临床和转化研究人员 失调。这些目标将为 ADRC 附属研究人员提供测试生物标志物的现成能力——一旦 在 AD 痴呆症中得到验证——在 AD 发病机制的最早阶段。